Pharmaceutical companies will lose an estimated $65 billion in sales by 2019 due to patent expirations of leading drugs, according to one research and consulting firm.
The companies that will likely be hardest hit include Otsuka, Eli Lilly and AstraZeneca, which has a research and development center in Waltham, according GlobalData.
Eli Lilly and AstraZeneca have seen profits fall in the central nervous system therapeutics market since 2010, with AstraZeneca losing the greatest share over the past three years, said Adam Dion, a GlobalData analyst covering healthcare industry dynamics. (Más)
The top 10 patent losses of 2015